Few peptides have produced as much published data in as short a time as retatrutide. Two peer-reviewed phase 2 trials (one in obesity, one in type 2 diabetes), a preclinical characterisation in Cell Metabolism, and an ongoing phase 3 development programme (TRIUMPH) make the molecule the most-discussed triple agonist in the metabolic research literature. This article walks through five findings the research community keeps coming back to.
This is not a clinical guide and does not recommend retatrutide for medical use. Retatrutide as supplied by NorexBio is research-grade peptide intended for in vitro laboratory and analytical research. For regulatory context: retatrutide is not yet approved for clinical use anywhere in the EU, the UK, or the United States.
1. 24.2% body-weight reduction at 48 weeks (phase 2 obesity, NEJM 2023)
Jastreboff et al., New England Journal of Medicine, 2023. A 48-week phase 2 trial in 338 adults with obesity randomised participants to placebo or retatrutide across dose arms from 1 mg to 12 mg. At the 12 mg arm, the trial reported a mean body-weight reduction of 24.2% at 48 weeks, the highest figure documented for any GLP-1-class agonist in a published clinical trial.
The figure is the single most-cited finding about retatrutide and drives most of the wider interest from researchers and clinical developers. It is phase 2 data, not phase 3, and the result should be read in that context until the TRIUMPH program reports.
2. Up to 2.16% HbA1c reduction in type 2 diabetes (phase 2, Lancet 2023)
Rosenstock et al., Lancet, 2023. A parallel phase 2 trial studied retatrutide in adults with type 2 diabetes over 36 weeks. At the 12 mg dose, HbA1c was reduced by up to 2.16 percentage points from baseline. The trial also reported clinically meaningful weight loss in the same cohort.
The dual signal, HbA1c down and weight down in the same cohort, is the mechanistically interesting finding: triple agonism touches both glucose homeostasis and energy balance in the same participants, which is the overarching hypothesis driving the development of the agonist class.
3. Triple agonism confirmed in preclinical work (Cell Metabolism 2022)
Coskun et al., Cell Metabolism, 2022. The characterisation paper for LY3437943 (retatrutide as a molecule) confirmed simultaneous activation of three receptors: the GLP-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).
This is the structural addition that distinguishes retatrutide from tirzepatide: tirzepatide activates GLP-1R and GIPR, retatrutide adds GCGR activation, which engages hepatic glucose output and energy expenditure. The preclinical pharmacology is the reason the molecule was advanced into phase 2 in the first place.
4. Dose-response with GLP-1-class tolerability in phase 2 data
Both phase 2 trials reported a dose-dependent effect: higher doses produced larger metabolic and weight-related changes. The safety profile resembled what has been reported across the incretin class, adverse events were predominantly gastrointestinal (nausea, vomiting, diarrhoea) and largely mild to moderate in intensity.
That is not a unique finding for retatrutide, but it is a relevant context point: the tolerability pattern does not differ dramatically from established GLP-1 agonists, so the research picture is dominated by effect size rather than by a novel adverse event class.
5. Phase 3 (TRIUMPH program) is ongoing and retatrutide is not approved
Eli Lilly's TRIUMPH program is the phase 3 development for retatrutide and covers multiple parallel trials in obesity and type 2 diabetes. Until the program reports out and is reviewed by regulators, retatrutide remains an investigational compound, not an approved medicine.
This is the fifth and most regulatorily important finding: every data point discussed above is phase 2. Effect sizes can shift in phase 3, safety signals can look different in a larger population, and approval decisions are based on the phase 3 totality, not on phase 2 headlines. Retatrutide as supplied by NorexBio remains research material for in vitro use throughout that period.
Summary
Five findings, five different layers: a headline number (24.2%), a mechanistically parallel finding at another indication (HbA1c in T2D), a preclinically confirmed triple-receptor profile, a dose-tolerability pattern, and a regulatory status that frames the rest. Full primary literature and DOI links live on our science page, and the handling and quality specifications for the research pens are on the quality page.